Core Viewpoint - UBS initiated coverage on Zai Lab (ZLAB.US) with a "Buy" rating and a target price of HKD 33.5 based on discounted cash flow (DCF) analysis, highlighting the company's growth potential and undervalued market position [1] Group 1: Company Performance - Zai Lab's stock rose over 2.8% pre-market, reaching USD 26.05 [1] - The core product VYVGART is expected to continue expanding its indications and increasing sales [1] Group 2: Product Pipeline - Several key candidate drugs are anticipated to receive approval, contributing to future growth [1] - The business development opportunities for ZL-1310 (DLL3ADC) and ZL-1503 (IL-13/IL-31R) are seen as significant growth drivers in the near term [1] Group 3: Market Perception - UBS believes the market has overlooked Zai Lab's short-term growth and business development potential [1]
美股异动｜再鼎医药盘前涨超2.8%，获瑞银给予“买入”评级+近期催化剂明确